2023 Press Releases
11-13-23 ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023
11-7-23 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023
10-5-23 ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023
08-29-23 ImmuCell Announces Submission of CMC Technical Section to the FDA
08-10-23 ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023
08-07-23 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
07-11-23 ImmuCell Announces Preliminary, Unaudited Sales Results Q2 2023
06-28-23 ImmuCell Announces Change in Timing of Anticipated FDA Submission
06-21-23 ImmuCell Appoints Bryan K. Gathagan to Board of Directors
06-15-23 ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility
05-16-23 ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
05-11-23 ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023
05-04-23 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023
04-05-23 ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023
02-21-23 ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022
02-15-23 ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022